Evidence map›Paper›PMID 32358063›Full record

ArticleThe Journal of biological chemistry2020

Co-targeting of CXCR4 and hedgehog pathways disrupts tumor-stromal crosstalk and improves chemotherapeutic efficacy in pancreatic cancer.

Mohammad Aslam Khan, Sanjeev Kumar Srivastava, Haseeb Zubair, Girijesh Kumar Patel, Sumit Arora, Moh'd Khushman, James Elliot Carter, Gregory Stephen Gorman, Seema Singh, Ajay Pratap Singh

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of biological chemistry, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed
2.8field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 43 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Article
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Article
  12. Targeting hedgehog-driven mechanisms of drug-resistant cancers.Frontiers in molecular biosciences · 2023
    Review
  13. Review
  14. Review
  15. Review
  16. Article
  17. Article
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Mohammad Aslam KhanDepartment of Pathology, College of Medicine, University of South Alabama, Mobile, Alabama.
Sanjeev Kumar SrivastavaDepartment of Pathology, College of Medicine, University of South Alabama, Mobile, Alabama.
Haseeb ZubairDepartment of Pathology, College of Medicine, University of South Alabama, Mobile, Alabama.
Girijesh Kumar PatelDepartment of Oncologic Sciences, Mitchell Cancer Institute, University of South Alabama, Mobile, Alabama.ORCID 0000-0003-4660-5876
Sumit AroraDepartment of Oncologic Sciences, Mitchell Cancer Institute, University of South Alabama, Mobile, Alabama.
Moh'd KhushmanDepartment of Medical Oncology, Mitchell Cancer Institute, University of South Alabama, Mobile, Alabama.ORCID 0000-0002-3095-5073
James Elliot CarterDepartment of Pathology, College of Medicine, University of South Alabama, Mobile, Alabama.
Gregory Stephen GormanPharmaceutical Sciences Research Institute, Samford University, Birmingham, Alabama.ORCID 0000-0003-4306-8884
Seema SinghDepartment of Pathology, College of Medicine, University of South Alabama, Mobile, Alabama.
Ajay Pratap SinghDepartment of Pathology, College of Medicine, University of South Alabama, Mobile, Alabama asingh@health.southalabama.edu.ORCID 0000-0003-3492-6330
USA Mitchell Cancer Institute · USSamford University · USUniversity of South Alabama · US

Funding

Targeting tumor-stromal interaction for pancreatic cancer therapyR01CA175772 · NCI · UNIVERSITY OF SOUTH ALABAMA · PI SINGH, AJAY PRATAP · 2014 to 2018
$1.9M
A novel molecular cross-talk driving pancreatic cancer progressionR01CA224306 · NCI · UNIVERSITY OF SOUTH ALABAMA · PI SINGH, AJAY PRATAP · 2018 to 2022
$1.7M
NCI NIH HHS R01 CA175772NCI NIH HHS R01 CA224306
6 · The paper itself

Abstract

Pancreatic cancer (PC) remains a therapeutic challenge because of its intrinsic and extrinsic chemoresistance mechanisms. Here, we report that C-

Indexed as

AnilidesAnimalsAntimetabolites, AntineoplasticBenzylaminesCell CommunicationCell SurvivalCoculture TechniquesCyclamsDeoxycytidineDrug Resistance, NeoplasmGemcitabineHedgehog ProteinsHeterocyclic CompoundsHumansMiceMice, NudeAnilidesAntimetabolites, AntineoplasticBenzylaminesCXCR4 protein, humanCyclamsDeoxycytidineGemcitabineHedgehog ProteinsHeterocyclic CompoundsHhAntag691plerixaforPyridinesReactive Oxygen SpeciesReceptors, CXCR4RNA, Small Interferingcancer stemnesschemoresistancechemotherapyC-X-C chemokine receptor type 4 (CXCR-4)pancreatic cancerpancreatic stellate cell (PSC)paracrine signalingsonic hedgehog (SHH)stromal cell

Identifiers

PMID32358063
PMCPMC7307206
OpenAlexW3021137054

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.